Pneumococcal Vaccine Timing for Adults

Make sure your patients are up to date with pneumococcal vaccination.

Two pneumococcal vaccines are recommended for adults:
- 13-valent pneumococcal conjugate vaccine (PCV13, Prevnar13®)
- 23-valent pneumococcal polysaccharide vaccine (PPSV23, Pneumovax®23)

**If patient and provider decide PCV13 is to be given:**
- Administer 1 dose of PCV13.
- Administer 1 dose of PPSV23 at least 1 year later.

**If patient and provider decide PCV13 is not to be given:**
- Administer 1 dose of PPSV23.
- Series complete. No additional doses indicated.

PCV13 and PPSV23 should not be administered during the same office visit.
When both are indicated, PCV13 should be given before PPSV23 whenever possible.
If either vaccine is inadvertently given earlier than the recommended window, do not repeat the dose.

One dose of PCV13 is recommended for adults:
- 19 years or older with certain medical conditions and who have not previously received PCV13. See Table 1 for specific guidance.
- Adults 65 years or older can discuss and decide, with their clinician, to receive PCV13 if they have not previously received a dose (shared clinical decision-making).

One dose of PPSV23 is recommended for adults:
- 65 years or older, regardless of previous history of vaccination with pneumococcal vaccines.
  - Once a dose of PPSV23 is given at age 65 years or older, no additional doses of PPSV23 should be administered.
- 19 through 64 years with certain medical conditions.
  - A second dose may be indicated depending on the medical condition. See Table 1 for specific guidance.

Adults 65 years or older without an immunocompromising condition, CSF* leak, or cochlear implant

For those who have not received any pneumococcal vaccines, or those with unknown vaccination history

If patient and provider decide PCV13 is **not** to be given:
- Administer 1 dose of PPSV23.

If patient and provider decide PCV13 is to be given:
- PCV13 (at ≥ 65 years) → At least 1 year apart → PPSV23 (at ≥ 65 years)
- Administer 1 dose of PCV13.
- Administer 1 dose of PPSV23 at least 1 year later.

For those who have previously received 1 dose of PPSV23 at ≥ 65 years and no doses of PCV13

If patient and provider decide PCV13 is **not** to be given:
- Series complete. No additional doses indicated.

If patient and provider decide PCV13 is to be given:
- PPSV23 (at ≥ 65 years) → At least 1 year apart → PCV13 (at ≥ 65 years)
- Administer 1 dose of PCV13 at least 1 year after the dose of PPSV23 for all adults, regardless of medical conditions.

*Cerebrospinal fluid leak

www.cdc.gov/pneumococcal/vaccination.html
### Pneumococcal vaccine timing for adults with certain medical conditions

**Indicated to receive 1 dose of PPSV23 at 19 through 64 years with no history of pneumococcal vaccination or unknown history**

If the patient and provider decide (through shared clinical decision-making) PCV13 is not to be given at age 65 years or older:
- Administer 1 dose of PPSV23 at 19 through 64 years.
- Administer 1 final dose of PPSV23 at 65 years or older. This dose should be given at least 5 years after the most recent dose of PPSV23.

**Includes adults with:** chronic heart, lung, or liver disease, diabetes mellitus, alcoholism. Also includes adults who smoke cigarettes.

**Indicated to receive 1 dose of PCV13 at ≥ 19 years and 1 or 2 doses of PPSV23 at 19 through 64 years**

For those who have not received any pneumococcal vaccines, or those with unknown vaccination history:
- Administer 1 dose of PCV13.
- Administer 1 dose of PPSV23 at **at least 8 weeks** later.
- Administer a second dose of PPSV23 at **at least 5 years** after the previous dose (*note: a second dose is not indicated for those with CSF leaks or cochlear implants*).
- Administer 1 final dose of PPSV23 at 65 years or older. This dose should be given **at least 5 years** after the most recent dose of PPSV23.

**Includes adults with:**
- cerebrospinal fluid (CSF) leaks*
- cochlear implants*
- sickle cell disease or other hemoglobinopathies
- congenital or acquired asplenia
- congenital or acquired immunodeficiencies
- HIV infection
- chronic renal failure
- nephrotic syndrome
- leukemia
- lymphoma
- Hodgkin disease
- generalized malignancy
- iatrogenic immunosuppression
- solid organ transplant
- multiple myeloma
<table>
<thead>
<tr>
<th>Medical indication</th>
<th>Underlying medical condition</th>
<th>PCV13 for ≥ 19 years Recommended</th>
<th>PPSV23* for 19 through 64 years Recommended</th>
<th>PCV13 at ≥ 65 years Recommended</th>
<th>PPSV23 at ≥ 65 years Recommended</th>
<th>Based on shared clinical decision-making</th>
<th>If PCV13 has been given, then give PPSV23 ≥ 1 year after PCV13</th>
</tr>
</thead>
<tbody>
<tr>
<td>None</td>
<td>None of the below</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Immunocompetent persons</td>
<td>Alcoholism</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Chronic heart disease†</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Chronic liver disease</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Chronic lung disease§</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Cigarette smoking</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Diabetes mellitus</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Cochlear implants</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
<td>✓</td>
<td>If no previous PCV13 vaccination</td>
</tr>
<tr>
<td></td>
<td>CSF leaks</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>≥ 8 weeks after PCV13 ≥ 5 years after any PPSV23 at &lt; 65 years</td>
</tr>
<tr>
<td>Persons with functional or anatomic asplenia</td>
<td>Congenital or acquired asplenia</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
<td>✓</td>
<td>If no previous PCV13 vaccination  ≥ 8 weeks after PCV13 ≥ 5 years after any PPSV23 at &lt; 65 years</td>
</tr>
<tr>
<td></td>
<td>Sickle cell disease/other hemoglobinopathies</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
<td>✓</td>
<td>If no previous PCV13 vaccination  ≥ 8 weeks after PCV13 ≥ 5 years after any PPSV23 at &lt; 65 years</td>
</tr>
<tr>
<td>Immunocompromised persons</td>
<td>Chronic renal failure</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Congenital or acquired immunodeficiencies¹</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Generalized malignancy</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>HIV infection</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Hodgkin disease</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Iatrogenic immunosuppression²</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Leukemia</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Lymphoma</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Multiple myeloma</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Nephrotic syndrome</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Solid organ transplant</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*This PPSV23 column only refers to adults 19 through 64 years of age. All adults 65 years of age or older should receive one dose of PPSV23 5 or more years after any prior dose of PPSV23, regardless of previous history of vaccination with pneumococcal vaccine. No additional doses of PPSV23 should be administered following the dose administered at 65 years of age or older.

†Including congestive heart failure and cardiomyopathies

‡Diseases requiring treatment with immunosuppressive drugs, including long-term systemic corticosteroids and radiation therapy

¶Includes B- (humoral) or T-lymphocyte deficiency, complement deficiencies (particularly C1, C2, C3, and C4 deficiencies), and phagocytic disorders (excluding chronic granulomatous disease)
Additional scenarios: completing the pneumococcal vaccination series for adults recommended to receive PCV13 ≥ 19 years

- Adults recommended to receive PCV13 at ≥ 19 years who already received 1 dose of PPSV23 at < 65 years
  - PPSV23 (at < 65 years)  
  - PCV13 (at ≥ 19 years)  
  - PPSV23 (at < 65 years)  
  - PPSV23 (at ≥ 65 years)

- Adults recommended to receive PCV13 at ≥ 19 years who already received 2 doses of PPSV23 at < 65 years and 1 dose of PPSV23 at ≥ 65 years
  - PPSV23 (at < 65 years)  
  - PPSV23 (at < 65 years)  
  - PPSV23 (at ≥ 65 years)  
  - PCV13 (at ≥ 19 years)  

- Adults recommended to receive PCV13 at ≥ 19 years who already received 2 doses of PPSV23 at < 65 years and 1 dose of PCV13 at < 65 years
  - PPSV23 (at < 65 years)  
  - PCV13 (at ≥ 19 years)  
  - PPSV23 (at ≥ 65 years)  

- Adults recommended to receive PCV13 at ≥ 19 years who already received 2 doses of PPSV23 at < 65 years and 1 dose of PCV13 at ≥ 65 years
  - PPSV23 (at < 65 years)  
  - PCV13 (at ≥ 19 years)  
  - PPSV23 (at ≥ 65 years)

For those who have already received 1 or more doses of PPSV23, or those with unclear documentation of the type of pneumococcal vaccine received:
- Administer 1 dose of PCV13 at least 1 year after the most recent pneumococcal vaccine dose.
- Administer a second dose of PPSV23 at least 8 weeks after PCV13 and at least 5 years after the previous dose of PPSV23 (note: a second dose is not indicated for those with CSF leaks or cochlear implants).
- Administer 1 final dose of PPSV23 at 65 years or older. This dose should be given at least 5 years after the most recent dose of PPSV23.

For those who have already received 1 dose of PCV13, do not administer an additional dose at 65 years or older.